Connective Tissue Growth Factor–Specific Monoclonal Antibody Therapy Inhibits Pancreatic Tumor Growth and Metastasis

2006 ◽  
Vol 66 (11) ◽  
pp. 5816-5827 ◽  
Author(s):  
Nadja Dornhöfer ◽  
Suzanne Spong ◽  
Kevin Bennewith ◽  
Ali Salim ◽  
Stephen Klaus ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Growth Factor ◽  
Connective Tissue ◽  
Tumor Growth ◽  
Pancreatic Tumor ◽  
Antibody Therapy ◽  
Tissue Growth ◽  
Monoclonal Antibody Therapy ◽  
Specific Monoclonal Antibody ◽  
Tumor Growth And Metastasis

scholarly journals Podocalyxin enhances breast tumor growth and metastasis and is a target for monoclonal antibody therapy

2015 ◽  
Vol 17 (1) ◽  
Author(s):  
Kimberly A Snyder ◽  
Michael R Hughes ◽  
Bradley Hedberg ◽  
Jill Brandon ◽  
Diana Canals Hernaez ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Tumor Growth ◽  
Breast Tumor ◽  
Antibody Therapy ◽  
Monoclonal Antibody Therapy ◽  
Tumor Growth And Metastasis

scholarly journals The Role of Tumor Cell–Derived Connective Tissue Growth Factor (CTGF/CCN2) in Pancreatic Tumor Growth

2009 ◽  
Vol 69 (3) ◽  
pp. 775-784 ◽  
Author(s):  
Kevin L. Bennewith ◽  
Xin Huang ◽  
Christine M. Ham ◽  
Edward E. Graves ◽  
Janine T. Erler ◽  
...  
Keyword(s):  
Growth Factor ◽  
Connective Tissue ◽  
Tumor Growth ◽  
Tumor Cell ◽  
Connective Tissue Growth Factor ◽  
Pancreatic Tumor ◽  
Tissue Growth

scholarly journals Cross-reactive antibody response to mRNA SARS-CoV-2 vaccine after recent COVID-19-specific monoclonal antibody therapy

2021 ◽  
Author(s):  
Stacey Schultz-Cherry ◽  
Maureen A McGargill ◽  
Paul G Thomas ◽  
Jeremie H Estepp ◽  
Aditya H Gaur ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Immune Responses ◽  
Antibody Response ◽  
Antibody Therapy ◽  
Antibody Responses ◽  
Monoclonal Antibody Therapy ◽  
Receptor Binding Domain ◽  
Specific Monoclonal Antibody ◽  
Vaccine Failure ◽  
Reactive Antibody

Abstract Efficacy of COVID-19 vaccines administered after COVID-19-specific monoclonal antibody is unknown, and ‘antibody interference’ might hinder immune responses leading to vaccine failure. In an IRB-approved prospective study, we found that an individual who received mRNA COVID-19 vaccination <40 days after COVID-19-specific monoclonal antibody therapy for symptomatic COVID-19 had similar post-vaccine antibody responses to SARS-CoV-2 receptor binding domain (RBD), for four important SARS-CoV-2 variants (B.1, B.1.1.7, B.1.351 and P.1), as other participants who were also vaccinated following COVID-19. Vaccination against COVID-19 shortly after COVID-19-specific monoclonal antibody can boost and expand antibody protection, questioning the need to delay vaccination in this setting.

Sign in / Sign up

Export Citation Format

Share Document